Bristol Myers Squibb’s Positive Zenbexus Data Put Multiple Myeloma Pipeline in Focus
Bristol Myers Squibb reported positive Phase 3 Zenbexus data, putting its multiple myeloma pipeline and potential regulatory path under investor scrut…
Teva Shares Rise Premarket After FDA Approves Once-Monthly Schizophrenia Treatment
Teva's ADRs climbed 4.5% premarket after FDA approval, putting its neuroscience pipeline and turnaround execution in focus.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
XORTX Therapeutics Jumps 16.7% as Gout Drug Program Moves Toward IND Filing
XORTX Therapeutics shares rose 16.7% as traders responded to progress toward an IND filing for the company’s accelerated…
FDA Expands Tecentriq Use to Stage III Colon Cancer in Roche Oncology Boost
FDA approval of Tecentriq in stage III colon cancer expands Roche’s oncology opportunity and adds a new competitive angl…
Teva Shares Rise as FDA Approves Once-Monthly Weltruza Schizophrenia Treatment
Teva shares rose 3.5% to 4.5% premarket after FDA approval of once-monthly Weltruza, sharpening focus on its specialty-m…
Crescent Energy’s $4.2 Billion Eagle Ford Deal Tests Balance Sheets and US Shale Consolidation
Crescent Energy’s Eagle Ford acquisition expands CRGY’s shale footprint while forcing investors to weigh financing press…
Lipocine’s 30% Surge After Canadian TLANDO Approval Puts Regulatory Catalysts in Focus
Lipocine’s LPCN shares rose 30% after Health Canada approved TLANDO, expanding the drug’s cross-border commercial opport…
Viatris-Pacira $36.50 Cash Deal Puts Merger-Arbitrage Focus on VTRS and PCRX
Viatris’s $36.50-per-share cash agreement to acquire Pacira puts PCRX’s deal spread and VTRS’s balance-sheet flexibility…
Lipocine Shares Jump 30% After Health Canada Approves TLANDO Testosterone Therapy
Lipocine shares surged 30% after Health Canada approved TLANDO, expanding the oral testosterone therapy’s availability i…
ArriVent BioPharma Plunges 47% After Phase III Lung Cancer Trial Miss
ArriVent’s $AVBP stock fell 46.98% after its FURVENT Phase III trial missed its primary endpoint, cutting market value t…
Viatris’ $36.50-a-Share Pacira Deal Signals Fresh Consolidation in Specialty Pharma
Viatris’ all-cash Pacira acquisition highlights continued US pharmaceutical consolidation and puts specialty-pharma valu…